114 related articles for article (PubMed ID: 1679365)
1. Dopamine receptor changes in untreated and (+)-PHNO-treated MPTP parkinsonian primates.
Alexander GM; Brainard DL; Gordon SW; Hichens M; Grothusen JR; Schwartzman RJ
Brain Res; 1991 May; 547(2):181-9. PubMed ID: 1679365
[TBL] [Abstract][Full Text] [Related]
2. Changes in brain dopamine receptors in MPTP parkinsonian monkeys following L-dopa treatment.
Alexander GM; Schwartzman RJ; Grothusen JR; Brainard L; Gordon SW
Brain Res; 1993 Oct; 625(2):276-82. PubMed ID: 8275309
[TBL] [Abstract][Full Text] [Related]
3. Changes in brain catecholamines and dopamine uptake sites at different stages of MPTP parkinsonism in monkeys.
Alexander GM; Schwartzman RJ; Brainard L; Gordon SW; Grothusen JR
Brain Res; 1992 Aug; 588(2):261-9. PubMed ID: 1356591
[TBL] [Abstract][Full Text] [Related]
4. Dyskinesias and tolerance induced by chronic treatment with a D1 agonist administered in pulsatile or continuous mode do not correlate with changes of putaminal D1 receptors in drug-naive MPTP monkeys.
Goulet M; Grondin R; Blanchet PJ; Bédard PJ; Di Paolo T
Brain Res; 1996 May; 719(1-2):129-37. PubMed ID: 8782872
[TBL] [Abstract][Full Text] [Related]
5. Differential effect of chronic dopaminergic treatment on dopamine D1 and D2 receptors in the monkey brain in MPTP-induced parkinsonism.
Graham WC; Sambrook MA; Crossman AR
Brain Res; 1993 Feb; 602(2):290-303. PubMed ID: 8095431
[TBL] [Abstract][Full Text] [Related]
6. Effect of chronic treatment with (+)-PHNO, a D2 agonist in MPTP-treated monkeys.
Gomez-Mancilla B; Bédard PJ
Exp Neurol; 1992 Aug; 117(2):185-8. PubMed ID: 1354166
[TBL] [Abstract][Full Text] [Related]
7. Preproenkephalin mRNA expression in the caudate-putamen of MPTP monkeys after chronic treatment with the D2 agonist U91356A in continuous or intermittent mode of administration: comparison with L-DOPA therapy.
Morissette M; Goulet M; Soghomonian JJ; Blanchet PJ; Calon F; Bédard PJ; Di Paolo T
Brain Res Mol Brain Res; 1997 Oct; 49(1-2):55-62. PubMed ID: 9387863
[TBL] [Abstract][Full Text] [Related]
8. Levodopa or D2 agonist induced dyskinesia in MPTP monkeys: correlation with changes in dopamine and GABAA receptors in the striatopallidal complex.
Calon F; Goulet M; Blanchet PJ; Martel JC; Piercey MF; Bédard PJ; Di Paolo T
Brain Res; 1995 May; 680(1-2):43-52. PubMed ID: 7663983
[TBL] [Abstract][Full Text] [Related]
9. Chronic CY 208-243 treatment of MPTP-monkeys causes regional changes of dopamine and GABAA receptors.
Gagnon C; Gomez-Mancilla B; Bédard PJ; Di Paolo T
Neurosci Lett; 1993 Nov; 163(1):31-5. PubMed ID: 7905197
[TBL] [Abstract][Full Text] [Related]
10. Antiparkinsonian activity of (+)-PHNO in the MPTP-treated common marmoset.
Nomoto M; Stahl S; Jenner P; Marsden CD
Mov Disord; 1987; 2(1):37-45. PubMed ID: 2904119
[TBL] [Abstract][Full Text] [Related]
11. Behavioural effects of (+)-4-propyl-9-hydroxynaphthoxazine in primates rendered parkinsonian with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Clarke CE; Boyce S; Sambrook MA; Stahl SM; Crossman AR
Naunyn Schmiedebergs Arch Pharmacol; 1988 Jul; 338(1):35-8. PubMed ID: 2907097
[TBL] [Abstract][Full Text] [Related]
12. Effect of adding the D-1 agonist CY 208-243 to chronic bromocriptine treatment of MPTP-monkeys: regional changes of brain dopamine receptors.
Gagnon C; Gomez-Mancilla B; Markstein R; Bédard PJ; Di Paolo T
Prog Neuropsychopharmacol Biol Psychiatry; 1995 Jul; 19(4):667-76. PubMed ID: 8588064
[TBL] [Abstract][Full Text] [Related]
13. Effects of chronic treatment of MPTP monkeys with bromocriptine alone or in combination with SKF 38393.
Rouillard C; Bédard PJ; Di Paolo T
Eur J Pharmacol; 1990 Aug; 185(2-3):209-15. PubMed ID: 2253695
[TBL] [Abstract][Full Text] [Related]
14. The effects of chronic levodopa treatment on pre- and postsynaptic markers of dopaminergic function in striatum of parkinsonian monkeys.
Rioux L; Frohna PA; Joyce JN; Schneider JS
Mov Disord; 1997 Mar; 12(2):148-58. PubMed ID: 9087972
[TBL] [Abstract][Full Text] [Related]
15. Changes of D1 and D2 dopamine receptor mRNA in the brains of monkeys lesioned with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: correction with chronic administration of L-3,4-dihydroxyphenylalanine.
Morissette M; Goulet M; Calon F; Falardeau P; Blanchet PJ; Bédard PJ; Di Paolo T
Mol Pharmacol; 1996 Nov; 50(5):1073-9. PubMed ID: 8913337
[TBL] [Abstract][Full Text] [Related]
16. Selective D2 receptor stimulation induces dyskinesia in parkinsonian monkeys.
Luquin MR; Laguna J; Obeso JA
Ann Neurol; 1992 May; 31(5):551-4. PubMed ID: 1350718
[TBL] [Abstract][Full Text] [Related]
17. Autoradiographic studies in animal models of hemi-parkinsonism reveal dopamine D2 but not D1 receptor supersensitivity. II. Unilateral intra-carotid infusion of MPTP in the monkey (Macaca fascicularis).
Graham WC; Clarke CE; Boyce S; Sambrook MA; Crossman AR; Woodruff GN
Brain Res; 1990 Apr; 514(1):103-10. PubMed ID: 2192772
[TBL] [Abstract][Full Text] [Related]
18. Chronic D1 and D2 dopaminomimetic treatment of MPTP-denervated monkeys: effects on basal ganglia GABA(A)/benzodiazepine receptor complex and GABA content.
Calon F; Morissette M; Goulet M; Grondin R; Blanchet PJ; Bédard PJ; Di Paolo T
Neurochem Int; 1999 Jul; 35(1):81-91. PubMed ID: 10403433
[TBL] [Abstract][Full Text] [Related]
19. Long-term treatment with l-DOPA and an mGlu5 receptor antagonist prevents changes in brain basal ganglia dopamine receptors, their associated signaling proteins and neuropeptides in parkinsonian monkeys.
Morin N; Jourdain VA; Morissette M; Grégoire L; Di Paolo T
Neuropharmacology; 2014 Apr; 79():688-706. PubMed ID: 24456747
[TBL] [Abstract][Full Text] [Related]
20. Effects of L-DOPA-therapy on dopamine D2 receptor mRNA expression in the striatum of MPTP-intoxicated parkinsonian monkeys.
Herrero MT; Augood SJ; Asensi H; Hirsch EC; Agid Y; Obeso JA; Emson PC
Brain Res Mol Brain Res; 1996 Nov; 42(1):149-55. PubMed ID: 8915594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
